Cereblon binding molecules in multiple myeloma.
Blood Rev
; 29(5): 329-34, 2015 Sep.
Article
en En
| MEDLINE
| ID: mdl-25843596
ABSTRACT
Immunomodulation is an established treatment strategy in multiple myeloma with thalidomide and its derivatives lenalidomide and pomalidomide as its FDA approved representatives. Just recently the method of action of these cereblon binding molecules was deciphered and results from large phase 3 trials confirmed the backbone function of this drug family in various combination therapies. This review details the to-date knowledge concerning mechanism of IMiD action, clinical applications and plausible escape mechanisms in which cells may become resistant/refractory to cereblon binding molecule based treatment.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Péptido Hidrolasas
/
Mieloma Múltiple
Límite:
Humans
Idioma:
En
Revista:
Blood Rev
Asunto de la revista:
HEMATOLOGIA
Año:
2015
Tipo del documento:
Article
País de afiliación:
Estados Unidos